Abstract
We apply the superiorization methodology to the intensity-modulated radiation therapy (IMRT) treatment planning problem. In superiorization, linear voxel dose inequality constraints are the fundamental modeling tool within which a feasibility-seeking projection algorithm will seek a feasible point. This algorithm is then perturbed with gradient descent steps to reduce a nonlinear objective function. Within the open-source inverse planning toolkit matRad, we implement a prototypical algorithmic framework for superiorization using the well-established Agmon, Motzkin, and Schoenberg (AMS) feasibility-seeking projection algorithm and common nonlinear dose optimization objective functions. Based on this prototype, we apply superiorization to intensity-modulated radiation therapy treatment planning and compare its performance with feasibility-seeking and nonlinear constrained optimization. For these comparisons, we use the TG119 water phantom and a head-and-neck patient of the CORT dataset. Bare feasibility-seeking with AMS confirms previous studies, showing it can find solutions that are nearly equivalent to those found by the established piece-wise least-squares optimization approach. The superiorization prototype solved the linearly constrained planning problem with similar performance to that of a general-purpose nonlinear constrained optimizer while showing smooth convergence in both constraint proximity and objective function reduction. Superiorization is a useful alternative to constrained optimization in radiotherapy inverse treatment planning. Future extensions with other approaches to feasibility-seeking, e.g., with dose-volume constraints and more sophisticated perturbations, may unlock its full potential for high-performant inverse treatment planning.
Connections
Explore this paper’s authors, topics and related work.
Building this map preview
BZPEER is loading the nearby papers, people, topics and institutions for this page.
Reviews 0
Write a review
No reviews yet.
Discussion 0
Add a comment
No comments yet.